# Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Source: https://onco.cc/trials/nct06516289/  
OnCo record `nct06516289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06516289 as recruiting, last updated 2024-12-12. Enrolment is 130 planned participants, an estimate. Interventions: HRS-1167, Famitinib, Camrelizumab. Primary measures include Safety run-in: Incidence rate of dose-limiting toxicities (DLTs); Safety run-in: adverse events (AEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06516289
- Phase: 2
- Setting: Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib/ HRS-1167, Famitinib and Camrelizumab: A Prospective, Open-label, Multicenter, Phase II Trial
- Sponsor: Fudan University

## Sources

- ClinicalTrials.gov NCT06516289: https://clinicaltrials.gov/study/NCT06516289

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct06516289.json